CYP2D6, NAT2 and CYP2E1 genetic polymorphisms in nonagenarians

Area of Science:

• Pharmacogenomics and Human Longevity Research
• Genetics of Aging and Disease Susceptibility

Background:

• Enzymatic polymorphisms influence the metabolism of xenobiotics, affecting carcinogen activation/deactivation.
• These genetic variations may impact the risk of cancers and degenerative diseases, potentially influencing longevity.

Purpose of the Study:

• To determine the distribution of polymorphisms in CYP2D6, NAT-2, and CYP2E1 genes in nonagenarians versus younger controls.
• To assess if specific genetic configurations of these enzyme polymorphisms are associated with extreme longevity.

Main Methods:

• Genotyping for CYP2D6, NAT-2, and CYP2E1 polymorphisms using DNA extracted from blood cells.
• Polymerase chain reaction and restriction fragment polymorphism techniques were employed.
• Study included 41 nonagenarians and two younger control groups (n=217 and n=137).

Main Results:

• No significant qualitative or quantitative differences were found in the studied genetic polymorphisms between nonagenarians and younger controls.
• A close parallelism in the distribution of these polymorphisms was observed across age groups.
• Enzymatic phenotypes did not differ between the elderly and younger cohorts.

Conclusions:

• Extreme longevity does not appear to be linked to specific configurations of CYP2D6, NAT-2, or CYP2E1 polymorphisms.
• Younger control groups may be suitable for studying these polymorphisms in age-related diseases.
• No age-related genetic differences in drug metabolism via these enzymes are expected in the very old.